Search Results - "Everly, M."

Reducing De Novo Donor‐Specific Antibody Levels during Acute Rejection Diminishes Renal Allograft Loss by Everly, M. J., Everly, J. J., Arend, L. J., Brailey, P., Susskind, B., Govil, A., Rike, A., Roy‐Chaudhury, P., Mogilishetty, G., Alloway, R. R., Tevar, A., Woodle, E. S.

“…The effect of de novo DSA detected at the time of acute cellular rejection (ACR) and the response of DSA levels to rejection therapy on renal allograft…”
Get full text

The Value of Protocol Biopsies to Identify Patients With De Novo Donor‐Specific Antibody at High Risk for Allograft Loss by Schinstock, C. A., Cosio, F., Cheungpasitporn, W., Dadhania, D. M., Everly, M. J., Samaniego‐Picota, M. D., Cornell, L., Stegall, M. D.

“…De novo donor‐specific antibody (dnDSA) is associated with antibody‐mediated rejection (AMR) and allograft loss, yet the allograft histology associated with…”
Get full text

Examining abiotic and biotic factors influencing specimen black oaks (Quercus kelloggii) in northern California to reimplement traditional ecological knowledge and promote ecosystem resilience post-wildfire by O'Gorman, Cory J., Bentley, Lisa Patrick, McKay, Clint, Purser, Margaret, Everly, Kylie M.

“…California black oak, Quercus kelloggii, plays an important role in the lifeways of many Indigenous tribes throughout California. Native peoples tend black…”
Get full text

Onset and progression of de novo donor-specific anti-human leukocyte antigen antibodies after BK polyomavirus and preemptive immunosuppression reduction by Dieplinger, G., Everly, M.J., Briley, K.P., Haisch, C.E., Bolin, P., Maldonado, A.Q., Kendrick, W.T., Kendrick, S.A., Morgan, C., Terasaki, P.I., Rebellato, L.M.

“…Background BK polyomavirus (BKPyV) viremia/nephropathy and reduction in immunosuppression following viremia may increase the risk of alloimmune activation and…”
Get full text

Proteasome Inhibition Reduces Donor-Specific Antibody Levels by Everly, M.J, Everly, J.J, Susskind, B, Brailey, P, Arend, L.J, Alloway, R.R, Roy-Chaudhury, P, Govil, A, Mogilishetty, G, Rike, A.H, Cardi, M, Wadih, G, Brown, E, Tevar, A, Woodle, E.S

“…Abstract Background Current antibody-mediated rejection (AMR) therapies (intravenous immunoglobulin, apheresis, rituximab, polyclonal antibodies) do not target…”
Get full text

Impact of the Presence and Duration of Donor-Specific Antibodies on Renal Function by Hoshino, J, Everly, M.J, Kaneku, H, Ubara, Y, Takaichi, K, Terasaki, P.I

“…Abstract Background Although anti-human leukocyte antigen (HLA) antibodies (DSA) is associated with graft loss, 3 things remain unclear: whether the duration…”
Get full text

Elimination of post-transplant donor-specific HLA antibodies with bortezomib by Idica, A, Kaneku, H, Everly, M J, Trivedi, H L, Feroz, A, Vanikar, A V, Shankar, V, Trivedi, V B, Modi, P R, Khemchandani, S I, Dave, S D, Terasaki, P I

“…We show the ability of bortezomib to remove donor-specific HLA antibody from kidney allograft patients, the drug acting as a proteasome inhibitor, providing…”
Get more information

Clonal deletion using total lymphoid irradiation with no maintenance immunosuppression in renal allograft recipients by Trivedi, H L, Kaneku, H, Terasaki, P I, Feroz, A, Vanikar, A V, Trivedi, V B, Khemchandani, S I, Dave, S D, Modi, P R, Jahr, F, Idica, A, Everly, M J

“…A total of 69 individuals received a kidney from a living donor after a TLI-based clonal deletion protocol with no post-transplant maintenance…”
Get more information

Characterization of the Chloroplast Cytochrome b6f Complex as a Structural and Functional Dimer by Huang, D, Everly, R. M, Cheng, R. H, Heymann, J. B, Schaegger, H, Sled, V, Ohnishi, T, Baker, T. S, Cramer, W. A

“…Size analysis of the cytochrome b6f complex by FPLC Superose-12 chromatography and Blue Native PAGE indicated a predominantly dimeric component with Mr =…”
Get full text

Donor-specific HLA antibody response in clonal deletion by Kaneku, H, Idica, A, Everly, M J, Terasaki, P I, Feroz, A, Vanikar, A V, Shankar, V, Trivedi, V B, Modi, P R, Khemchandani, S I, Dave, S D, Trivedi, H L

“…1. A total of 61 patients were treated with a clonal deletion protocol and transplanted without planned post-transplant immunosuppression. 2. Twenty-nine (48%)…”
Get more information

Novel translocation in acute megakaryoblastic leukemia (AML-M7) by TORETSKY, Jeffrey A, EVERLY, Eileen M, PADILLA-NASH, Hesed M, CHEN, Allen, ABRUZZO, Lynne V, ESKENAZI, Allen E, FRANTZ, Chris, RIED, Thomas, STAMBERG, Judith

“…The authors report a unique translocation in a patient with M7 acute myeloid leukemia and review the literature. A 22-month-old girl without Down syndrome was…”
Get full text

The Role of Immunoglobulin-G Subclasses and C1q in De Novo HLA-DQ Donor-Specific Antibody Kidney Transplantation Outcomes by Freitas, Maria Cecilia S, Rebellato, Lorita M, Ozawa, Miyuki, Nguyen, Anh, Sasaki, Nori, Everly, Matthew, Briley, Kimberly P, Haisch, Carl E, Bolin, Paul, Parker, Karen, Kendrick, William T, Kendrick, Scott A, Harland, Robert C, Terasaki, Paul I

“…BACKGROUNDAnti–HLA-DQ antibodies are the predominant HLA class II donor-specific antibodies (DSAs) after transplantation. Recently, de novo DQ DSA has been…”
Get full text

Therapeutic Endpoints in a Preemtive DSA Treatment Protocol with Bortezomib: 1958 by Everly, M., Terasaki, P. I., Trivedi, H. L.

Get full text

Therapeutic Endpoints in a Preemtive DSA Treatment Protocol with Bortezomib: 1958 by Everly, M., Terasaki, P. I., Trivedi, H. L.

Get full text

BORTEZOMIB EFFECTIVENESS IN 69 PATIENTS TREATED IN 29 CENTERS WORLDWIDE: 1046 by Everly, M. J., Terasaki, P. I.

Get full text

Selective Depletion of Complement-Binding Anti-HLA Antibodies Following BLyS Neutralization with Belimumab: Abstract# B3028 by Kamoun, M., Trofe-Clark, J., Migone, T., Kearns, J., Everly, M., Terasaki, P., Prak, Luning E., Abt, P., Naji, A.

Get full text

Reductions in Immunosuppression Are Associated With IgM-to-IgG DSA Isotype Switch and Risk of Post-DSA Allograft Loss: Abstract# 2214 by Maldonado, A., Everly, M., Rebellato, L., Haisch, C., Briley, K., Bolin, P., Kendrick, W., Kendrick, S., Morgan, C., Dieplinger, G., Harland, R., Terasaki, P.

Get full text

Actual 5-Year Post-De Novo DSA Outcomes in Low Risk Primary Kidney Transplant Recipients: Abstract# B856 by Everly, M., Rebellato, L., Haisch, C., Briley, K., Bolin, P., Kendrick, W., Kendrick, S., Morgan, C., Dieplinger, G., Maldonado, A., Harland, R., Terasaki, P.

Get full text

Changes in Successive Measures of De Novo DSA Intensity Predict Development of Renal Allograft Dysfunction: Abstract# B868 by Dieplinger, G., Everly, M., Rebellato, L., Haisch, C., Briley, K., Bolin, P., Kendrick, W., Kendrick, S., Morgan, C., Harland, R., Terasaki, P.

Get full text

Rising Incidence of De Novo Anti-HLA DSA in African American Renal Transplant Recipients Over a Decade: Abstract# A237 by Dieplinger, G., Everly, M., Rebellato, L., Haisch, C., Briley, K., Bolin, P., Kendrick, W., Kendrick, S., Morgan, C., Hoermann, M., Maldonado, A., Harland, R., Terasaki, P.

Get full text